查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
細胞活力測定市場規模、份額和趨勢分析報告：按產品（消耗品、儀器）、應用（藥物發現與開發、幹細胞研究）、最終用戶、地區、細分市場預測 2023-2030 年
市場調查報告書
商品編碼
1171087

細胞活力測定市場規模、份額和趨勢分析報告：按產品（消耗品、儀器）、應用（藥物發現與開發、幹細胞研究）、最終用戶、地區、細分市場預測 2023-2030 年

Cell Viability Assays Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Application (Drug Discovery & Development, Stem Cell Research), By End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

細胞活力檢測市場的增長和趨勢

根據 Grand View Research, Inc. 的最新報告，到 2030 年，細胞活力檢測的全球市場規模預計將達到 30.1 億美元，2023 年至 2030 年的複合年增長率為 9.94%。我來了。 慢性病和傳染病患病率的上升以及對基於細胞的療法的日益關注正在增加市場的增長前景。 此外，增加對基於細胞的研究的資助和增加自動化設備的使用是推動細胞活力測定 (CVA) 市場的主要因素。

基於細胞的研究不斷增加的資金和投資正在擴大細胞存活測定的增長前景。 例如，2022 年 5 月，加州再生醫學研究所 (CIRM) 宣布投資 1100 萬美元用於測試細胞療法臨床試驗，以幫助喉癌患者從放射療法的毀滅性副作用中痊癒。 因此，增加對基於細胞的研究的資助預計將在預測期內促進市場增長。

此外，領先的公司不斷開發尖端技術以滿足不斷增長的需求並抓住尚未開發的機會。 例如，2022 年 4 月，Molecular Devices, LLC 宣布推出 SpectraMax Mini 多模式微孔板讀板機，適用於包括細胞活力在內的多種應用。 它是一種緊湊、經濟高效的解決方案，集成了數據分析軟件和協議控制，可實現快速數據生成和分析。 預計此類創新將推動 CVA 在生物技術和學術實驗室中的採用。

預計 COVID-19 的爆發將對市場增長產生積極影響。 細胞計數和活力測定用於支持 COVID-19 疫苗研究。 COVID-19 研究中最常用的 CVA 包括活/死（EarlyTox 活/死檢測試劑盒）染色、MTT 檢測、轉染效率和細胞活力（CellTiter-Glo 發光細胞活力檢測）。 因此，預計 COVID-19 流行病將增加這些檢測的使用，這有望促進市場增長。

對開發基於細胞的療法的日益關注正在推動市場的增長。 增加臨床試驗、FDA 批准和主要參與者的合作夥伴關係等戰略舉措正在推動市場增長。 例如，2022 年 1 月，百時美施貴寶 (Bristol-Myers Squibb) 和 Century Therapeutics 展開研究合作，開發四種用於血液惡性腫瘤和實體瘤的誘導多能幹細胞。 這些努力有望增加 CVA 在幹細胞療法開發中的應用，推動預測期內的增長。

另一方面，試劑的高成本和細胞活力測定在 3D 細胞培養中的應用有限可能會在一定程度上限制市場增長。 例如，在 3D 細胞培養中進行細胞活力測定時，測定試劑可能很難到達微組織的中心。 因此，無法獲得準確的測量結果。 然而，主要參與者正在不斷努力開發新穎且具有成本效益的試劑和技術來克服這一限制，這將為市場創造增長前景。

細胞活力檢測市場報告要點

按產品劃分，耗材部分在 2022 年所佔份額最大。 這是由於製藥和生物技術公司、幹細胞研究和診斷對 CVA 的需求不斷增加，這反過來將推動市場增長。

從應用來看，2022年藥物發現與開發領域將佔據第二大份額。 這是因為越來越多地使用 CVA 來估計藥物發現和開發過程中與細胞死亡相關的細胞變化。

在最終用戶方面，生物製藥和製藥公司部門將在 2022 年佔據最大份額，因為細胞活力測定在藥物中廣泛使用，以評估開發藥物對細胞的影響。佔

由於政府投資舉措的增加、癌症等慢性病發病率的增加以及用於臨床和實驗室研究的高質量基礎設施的存在，北美將在 2022 年佔據超過 35.0% 的份額。主導著世界市場。

由於對新療法的需求不斷增加、政府增加研發投資以及基礎設施的快速發展，預計亞太地區未來將經歷顯著增長。

內容

第1章研究方法論

  • 市場細分和範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查的詳細信息
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐個國家/地區進行市場估算
  • 全球市場：CAGR 計算
  • 調查假設
  • 二級信息列表
  • 主要信息列表
  • 目的
  • 縮寫列表

第2章市場定義

第 3 章執行摘要

  • 市場概覽

第 4 章全球細胞活力測定市場變量、趨勢和範圍

  • 細胞活力檢測市場譜系展望
    • 母公司市場展望
  • 描繪滲透率和增長前景
  • 監管框架
  • 市場驅動因素分析
    • 人們對開發基於細胞的療法越來越感興趣
    • 增加對細胞研究的資助
    • 細胞活力測定的技術進步
  • 市場製約因素分析
    • 試劑和設備的高成本可能會限制細胞活力測定的採用
    • 細胞活力測定對 3D 細胞培養的適用性有限
  • 市場機會分析
    • 越來越關注幹細胞研究
  • 波特的五力分析
  • 細胞活力檢測市場：COVID-19 影響分析

第 5 章細胞活力測定市場 - 細分分析，副產品，2018-2030（百萬美元）

  • 全球細胞活力檢測市場：產品差異分析
  • 消耗品
    • 試劑和檢測試劑盒
      • 染料排斥分析
      • 比色法
      • 熒光分析
      • 發光分析
    • 微孔板
  • 設備
    • 分光光度計
    • 顯微鏡
    • 細胞圖像分析系統
    • 流式細胞儀
    • 其他

第 6 章細胞活力檢測市場 - 細分分析，按應用，2018-2030（百萬美元）

  • 全球細胞存活分析市場：應用差異分析
  • 藥物發現和開發
  • 幹細胞研究
  • 診斷

第 7 章細胞活力測定市場細分分析，按最終用戶，2018-2030 年（百萬美元）

  • 細胞活力檢測市場：最終用戶差異分析
  • 生物製藥和製藥公司
  • CRO 和 CMO
  • 學術和研究機構
  • 診斷實驗室

第 8 章細胞活力檢測市場：-按地區劃分的細分分析，2018-2030 年（百萬美元）

  • 細胞存活分析市場：區域差異分析
  • 北美
    • SWOT 分析
    • 美國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 加拿大
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 歐洲
    • SWOT 分析
    • 德國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 英國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 法國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 意大利
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 西班牙
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 丹麥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 瑞典
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 挪威
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 亞太地區
    • SWOT 分析
    • 日本
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 中國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 印度
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 韓國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 澳大利亞
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 泰國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 拉丁美洲
    • SWOT 分析
    • 巴西
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 墨西哥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿根廷
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 中東和非洲
    • SWOT 分析
    • 南非
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 沙特阿拉伯
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿拉伯聯合酋長國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 科威特
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景

第9章競爭格局

  • 市場進入者概覽
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories Inc.
    • Merck KGaA
    • BD
    • PerkinElmer Inc.
    • Promega Corporation
    • Biotium
    • Creative Bioarray
    • Abcam Plc
    • Charles River Laboratories
  • 財務業績
  • 參與者分類
    • 市場領導者
      • 2022 年細胞活力檢測市場份額分析
    • 戰略規劃
      • 分機
      • 得到
      • 協作
      • 產品/服務發布
      • 夥伴關係
      • 其他
Product Code: GVR-4-68040-008-0

Cell Viability Assays Market Growth & Trends:

The global cell viability assays market size is expected to reach USD 3.01 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.94% from 2023 to 2030. The rising prevalence of chronic and infectious diseases and the increasing focus on cell-based therapeutics are expanding the growth prospects of the market. In addition, growing funding for cell-based research and increasing use of automated instruments are the key factors driving the market for cell viability assays (CVAs).

Increasing funding and investments for cell-based research are expanding growth prospects for cell viability assays. For instance, in May 2022, the California Institute for Regenerative Medicine (CIRM) announced an investment of USD 11 million to fund a cell therapy clinical trial testing to help throat cancer patients to heal from the devastating side effects of radiation therapy. Thus, increasing funding for cell-based research is predicted to boost market growth during the projection period.

Furthermore, major players are continuously developing sophisticated technologies to meet the rising demand and capture untapped opportunities. For instance, in April 2022, Molecular Devices, LLC introduced SpectraMax Mini Multi-Mode Microplate Reader for various applications, including cell viability. It is a compact and cost-effective solution integrated with data analysis software and protocol control for rapid data generation and analysis. Such technological innovations are anticipated to increase the adoption of CVAs in biotech and academic laboratories.

The COVID-19 pandemic is expected to positively influence market growth. The cell counting and viability assay are used to aid COVID-19 vaccine research. The most frequently used CVAs in COVID-19 research include Live/Dead (EarlyTox Live/Dead Assay Kit) staining, MTT assay, Transfection efficiency, and Cell viability (CellTiter-Glo Luminescent Cell Viability Assay). As a result, the usage of these assays is projected to increase due to the COVID-19 pandemic, which, in turn, is anticipated to boost the market growth.

The rising focus on the development of cell-based therapeutics is accelerating market growth. Increasing clinical trials, FDA approvals, and strategic initiatives such as collaborations by major players are boosting the market growth. For instance, in January 2022, Bristol Myers Squibb and Century Therapeutics entered into a research collaboration to develop four induced pluripotent stem cells for hematologic malignancies and solid tumors. Such initiatives are projected to increase the application of CVAs during the development of stem cell therapeutics, thereby propelling growth during the forecast years.

On the other hand, the high cost of reagents and limitations in the applicability of cell viability assay for 3D cell culture may restrict the market growth to a certain extent. For instance, while performing the cell viability assay in 3D cell culture, the assay regents may have difficulty reaching the center of microtissues. Thus, accurate results of the assay cannot be determined. However, key players are continuously striving for developing novel and cost-effective reagents and techniques to overcome the limitations, which is likely to create growth prospects for the market.

Cell Viability Assays Market Report Highlights:

  • By product, the consumables segment held the largest share in 2022. This is attributed to the increase in the requirement of CVAs for pharmaceutical and biotechnology companies, stem cell research, and diagnostics, which, in turn, is likely to fuel the market growth
  • By application, the drug discovery and development segment held the second-largest share in 2022. This is attributed to an increase in the applications of CVAs to estimate the cellular variations related to cell death during the drug discovery and development
  • By end-user, the biopharmaceutical and pharmaceutical companies segment held the largest share in 2022 owing to the widespread use of cell viability assay in pharmaceuticals to evaluate the influence of developed agents on cells
  • North America dominated the global market with over 35.0% share in 2022 due to a rise in investment initiatives by the government, increasing incidence of chronic diseases such as cancer, and the presence of high-quality infrastructure for clinical and laboratory research
  • Asia Pacific is expected to grow considerably in the future owing to the rising demand for novel therapeutics, increasing R&D investment by governments, and rapid infrastructural development

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity flow approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using a bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

  • 3.1 Market Summary

Chapter 4 Global Cell Viability Assay Market Variables, Trends, & Scope

  • 4.1 Cell Viability Assay Market Lineage Outlook
    • 4.1.1 Parent Market Outlook
  • 4.2 Penetration and Growth Prospect Mapping
  • 4.3 Regulatory Framework
  • 4.4 Market Driver Analysis
    • 4.4.1 Rising focus on the development of cell-based therapeutics
    • 4.4.2 Growing funding for cell-based research
    • 4.4.3 Technological advancements in cell viability assays
  • 4.5 Market Restraint Analysis
    • 4.5.1 High cost of reagents and instruments may limit the adoption of cell viability assays
    • 4.5.2 Limitations in the applicability of cell viability assays for 3D cell culture
  • 4.6 Market Opportunity Analysis
    • 4.6.1 Growing emphasis on stem cell research
  • 4.7 Porter's Five Forces Analysis
  • 4.8 Cell Viability Assay Market: COVID-19 Impact Analysis

Chapter 5 Cell Viability Assay Market - Segment Analysis, by product, 2018 - 2030 (USD Million)

  • 5.1 Global Cell Viability Assay Market: Product Movement Analysis
  • 5.2 Consumables
    • 5.2.1 Consumables market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.2 Reagents and Assay Kits
      • 5.2.2.1 Reagents and assay kits, by type market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.2.2.2 Dye exclusion assays
      • 5.2.2.2.1 Dye exclusion assays market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.2.2.3 Colorimetric assays
      • 5.2.2.3.1 Colorimetric assays market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.2.2.4 Fluorometric assays
      • 5.2.2.4.1 Fluorometric assays market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.2.2.5 Luminometric assays
      • 5.2.2.5.1 Luminometric assays market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.3 Microplates
      • 5.2.2.1 Microplates market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Instruments
    • 5.3.1 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.2 Spectrophotometer
      • 5.3.2.1 Spectrophotometer market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.3 Microscopy
      • 5.3.3.1 Microscopy market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.4 Cell Imaging and Analysis System
      • 5.3.4.1 Cell imaging and analysis system market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.5 Flow Cytometry
      • 5.3.5.1 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.6 Others
      • 5.3.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Cell Viability Assay Market- Segment Analysis, by Application, 2018 - 2030 (USD Million)

  • 6.1 Global Cell Viability Assay Market: Application Movement Analysis
  • 6.2 Drug Discovery and Development
    • 6.2.1 Drug discovery and development market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Stem Cell Research
    • 6.3.1 Stem cell research market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Diagnostics
    • 6.4.1 Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Cell Viability Assay Market- Segment Analysis, by End-user, 2018 - 2030 (USD Million)

  • 7.1 Cell Viability Assay Market: End-user Movement Analysis
  • 7.2 Biopharmaceutical & Pharmaceutical Companies
    • 7.2.1 Biopharmaceutical & pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3 CROs & CMOs
    • 7.3.1 CROs & CMOs market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4. Academic & Research Institutes
    • 7.4.1 Academic & research institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Diagnostic Labs
    • 7.5.1 Diagnostic labs market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Cell Viability Assay Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 8.1 Cell Viability Assay Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 SWOT Analysis
      • 8.2.1.1 North America cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.2.1.2 North America cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.2.1.3 North America cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.2.2 U.S.
      • 8.2.2.1 Key Country Dynamics
      • 8.2.2.2 Target Disease Prevalence
      • 8.2.2.3 Competitive Scenario
      • 8.2.2.4 Regulatory Framework
      • 8.2.2.5 Reimbursement Scenario
      • 8.2.2.6 U.S. cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.2.2.7 U.S. cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.2.2.8 U.S. cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Key Country Dynamics
      • 8.2.3.2 Target Disease Prevalence
      • 8.2.3.3 Competitive Scenario
      • 8.2.3.4 Regulatory Framework
      • 8.2.3.5 Reimbursement Scenario
      • 8.2.3.6 Canada cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.2.3.7 Canada cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.2.3.8 Canada cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3 Europe
    • 8.3.1 SWOT Analysis
      • 8.3.1.1 Europe cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.1.2 Europe cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.1.4 Europe cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.2 Germany
      • 8.3.2.1 Key Country Dynamics
      • 8.3.2.2 Target Disease Prevalence
      • 8.3.2.3 Competitive Scenario
      • 8.3.2.4 Regulatory Framework
      • 8.3.2.5 Reimbursement Scenario
      • 8.3.2.6 Germany cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.2.7 Germany cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.2.8 Germany cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.3 U.K.
      • 8.3.3.1 Key Country Dynamics
      • 8.3.3.2 Target Disease Prevalence
      • 8.3.3.3 Competitive Scenario
      • 8.3.3.4 Regulatory Framework
      • 8.3.3.5 Reimbursement Scenario
      • 8.3.3.6 U.K. cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.3.7 U.K. cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.3.8 U.K. cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.4 France
      • 8.3.4.1 Key Country Dynamics
      • 8.3.4.2 Target Disease Prevalence
      • 8.3.4.3 Competitive Scenario
      • 8.3.4.4 Regulatory Framework
      • 8.3.4.5 Reimbursement Scenario
      • 8.3.4.6 France cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.4.7 France cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.4.8 France cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.5 Italy
      • 8.3.5.1 Key Country Dynamics
      • 8.3.5.2 Target Disease Prevalence
      • 8.3.5.3 Competitive Scenario
      • 8.3.5.4 Regulatory Framework
      • 8.3.5.5 Reimbursement Scenario
      • 8.3.5.6 Italy cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.5.7 Italy cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.5.8 Italy cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.6 Spain
      • 8.3.6.1 Key Country Dynamics
      • 8.3.6.2 Target Disease Prevalence
      • 8.3.6.3 Competitive Scenario
      • 8.3.6.4 Regulatory Framework
      • 8.3.6.5 Reimbursement Scenario
      • 8.3.6.6 Spain cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.6.7 Spain cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.6.8 Spain cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.7 Denmark
      • 8.3.7.1 Key Country Dynamics
      • 8.3.7.2 Target Disease Prevalence
      • 8.3.7.3 Competitive Scenario
      • 8.3.7.4 Regulatory Framework
      • 8.3.7.5 Reimbursement Scenario
      • 8.3.7.6 Denmark cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.7.7 Denmark cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.7.8 Denmark cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.8 Sweden
      • 8.3.8.1 Key Country Dynamics
      • 8.3.8.2 Target Disease Prevalence
      • 8.3.8.3 Competitive Scenario
      • 8.3.8.4 Regulatory Framework
      • 8.3.8.5 Reimbursement Scenario
      • 8.3.8.6 Sweden cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.8.7 Sweden cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.8.8 Sweden cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.9 Norway
      • 8.3.9.1 Key Country Dynamics
      • 8.3.9.2 Target Disease Prevalence
      • 8.3.9.3 Competitive Scenario
      • 8.3.9.4 Regulatory Framework
      • 8.3.9.5 Reimbursement Scenario
      • 8.3.9.6 Norway cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.9.7 Norway cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.9.8 Norway cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 SWOT Analysis
      • 8.4.1.1 Asia Pacific cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.1.2 Asia Pacific cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.1.3 Asia Pacific cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.2 Japan
      • 8.4.2.1 Key Country Dynamics
      • 8.4.2.2 Target Disease Prevalence
      • 8.4.2.3 Competitive Scenario
      • 8.4.2.4 Regulatory Framework
      • 8.4.2.5 Reimbursement Scenario
      • 8.4.2.6 Japan cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.2.7 Japan cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.2.8 Japan cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.3 China
      • 8.4.3.1 Key Country Dynamics
      • 8.4.3.2 Target Disease Prevalence
      • 8.4.3.3 Competitive Scenario
      • 8.4.3.4 Regulatory Framework
      • 8.4.3.5 Reimbursement Scenario
      • 8.4.3.6 China cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.3.7 China cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.3.8 China cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.4 India
      • 8.4.4.1 Key Country Dynamics
      • 8.4.4.2 Target Disease Prevalence
      • 8.4.4.3 Competitive Scenario
      • 8.4.4.4 Regulatory Framework
      • 8.4.4.5 Reimbursement Scenario
      • 8.4.4.6 India cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.4.7 India cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.4.8 India cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.5 South Korea
      • 8.4.5.1 Key Country Dynamics
      • 8.4.5.2 Target Disease Prevalence
      • 8.4.5.3 Competitive Scenario
      • 8.4.5.4 Regulatory Framework
      • 8.4.5.5 Reimbursement Scenario
      • 8.4.5.6 South Korea cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.5.7 South Korea cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.5.8 South Korea cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.6 Australia
      • 8.3.9.1 Key Country Dynamics
      • 8.4.6.2 Target Disease Prevalence
      • 8.4.6.3 Competitive Scenario
      • 8.4.6.4 Regulatory Framework
      • 8.4.6.5 Reimbursement Scenario
      • 8.4.6.6 Australia cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.6.7 Australia cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.6.8 Australia cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.7 Thailand
      • 8.4.7.1 Key Country Dynamics
      • 8.4.7.2 Target Disease Prevalence
      • 8.4.7.3 Competitive Scenario
      • 8.4.7.4 Regulatory Framework
      • 8.4.7.5 Reimbursement Scenario
      • 8.4.7.6 Thailand cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.7.7 Thailand cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.7.8 Thailand cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.5 Latin America
    • 8.5.1 SWOT Analysis
      • 8.5.1.1 Latin America cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.5.1.2 Latin America cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.5.1.3 Latin America cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Key Country Dynamics
      • 8.5.2.2 Target Disease Prevalence
      • 8.5.2.3 Competitive Scenario
      • 8.5.2.4 Regulatory Framework
      • 8.5.2.5 Reimbursement Scenario
      • 8.5.2.6 Brazil cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.5.2.7 Brazil cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.5.2.8 Brazil cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.3 Mexico
      • 8.5.3.1 Key Country Dynamics
      • 8.5.3.2 Target Disease Prevalence
      • 8.5.3.3 Competitive Scenario
      • 8.5.3.4 Regulatory Framework
      • 8.5.3.5 Reimbursement Scenario
      • 8.5.3.6 Mexico cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.5.3.7 Mexico cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.5.3.8 Mexico cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.4 Argentina
      • 8.5.4.1 Key Country Dynamics
      • 8.5.4.2 Target Disease Prevalence
      • 8.5.4.3 Competitive Scenario
      • 8.5.4.4 Regulatory Framework
      • 8.5.4.5 Reimbursement Scenario
      • 8.5.4.6 Argentina cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.5.4.7 Argentina cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.5.4.8 Argentina cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.6 MEA
    • 8.6.1 SWOT Analysis
      • 8.6.1.1 MEA cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.1.2 MEA cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.1.3 MEA cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.2 South Africa
      • 8.6.4.1 Key Country Dynamics
      • 8.6.2.2 Target Disease Prevalence
      • 8.6.2.3 Competitive Scenario
      • 8.6.2.4 Regulatory Framework
      • 8.6.2.5 Reimbursement Scenario
      • 8.6.2.6 Argentina cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.2.7 Argentina cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.2.8 Argentina cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.3 Saudi Arabia
      • 8.6.3.1 Key Country Dynamics
      • 8.6.3.2 Target Disease Prevalence
      • 8.6.3.3 Competitive Scenario
      • 8.6.3.4 Regulatory Framework
      • 8.6.3.5 Reimbursement Scenario
      • 8.6.3.6 Saudi Arabia cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.3.7 Saudi Arabia cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.3.8 Saudi Arabia cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.4 UAE
      • 8.6.4.1 Key Country Dynamics
      • 8.6.4.2 Target Disease Prevalence
      • 8.6.4.3 Competitive Scenario
      • 8.6.4.4 Regulatory Framework
      • 8.6.4.5 Reimbursement Scenario
      • 8.6.4.6 UAE cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.4.7 UAE cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.4.8 UAE cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.5 Kuwait
      • 8.6.5.1 Key Country Dynamics
      • 8.6.5.2 Target Disease Prevalence
      • 8.6.5.3 Competitive Scenario
      • 8.6.5.4 Regulatory Framework
      • 8.6.5.5 Reimbursement Scenario
      • 8.6.5.6 Kuwait cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.5.7 Kuwait cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.5.8 Kuwait cell viability assay market, by end-user, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Participant's overview
    • 9.1.1 Thermo Fisher Scientific Inc.
    • 9.1.2 Agilent Technologies, Inc.
    • 9.1.3 Bio-Rad Laboratories Inc.
    • 9.1.4 Merck KGaA
    • 9.1.5 BD
    • 9.1.6 PerkinElmer Inc.
    • 9.1.7 Promega Corporation
    • 9.1.8 Biotium
    • 9.1.9 Creative Bioarray
    • 9.1.10 Abcam Plc
    • 9.1.11 Charles River Laboratories
  • 9.2 Financial performance
  • 9.3 Participant categorization
    • 9.3.1 Market leaders
      • 9.3.1.1 Cell viability assay market share analysis, 2022
    • 9.3.2 Strategy mapping
      • 9.3.2.1 Expansion
      • 9.3.2.2 Acquisition
      • 9.3.2.3 Collaborations
      • 9.3.2.4 Product/service launch
      • 9.3.2.5 Partnerships
      • 9.3.2.6 Others

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 4. Global cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 5. Global cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 6. Global cell viability assay market, by region, 2018 - 2030 (USD Million)
  • Table 7. North America cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 9. North America cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 10. North America cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 11. U.S. Cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 12. U.S. Cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 13. U.S. Cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 14. Canada cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 15. Canada cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 16. Canada cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 17. Europe cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 18. Europe cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 19. Europe cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 20. Europe cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 21. U.K. cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 22. U.K. cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 23. U.K. cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 24. Germany cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 25. Germany cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 26. Germany cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 27. France cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 28. France cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 29. France cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 30. Italy cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 31. Italy cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 32. Italy cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 33. Spain cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 34. Spain cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 35. Spain cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 36. Denmark cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 37. Denmark cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 38. Denmark cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 39. Sweden cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 40. Sweden cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 41. Sweden cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 42. Norway cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 43. Norway cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 44. Norway cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 47. Asia Pacific cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 48. Asia pacific cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 49. China cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 50. China cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 51. China cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 52. India cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 53. India cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 54. India cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 55. Japan cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 56. Japan cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 57. Japan cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 58. Thailand cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 59. Thailand cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 60. Thailand cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 61. Australia cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 62. Australia cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 63. Australia cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 64. South Korea cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 65. South Korea cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 66. South Korea cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 67. Latin America cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 68. Latin America cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 69. Latin America cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 70. Latin America cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 71. Brazil cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 72. Brazil cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 73. Brazil cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 74. Mexico cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 75. Mexico cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 76. Mexico cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 77. Argentina cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 78. Argentina cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 79. Argentina cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 84. South Africa cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 85. South Africa cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 86. South Africa cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 90. UAE cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 91. UAE cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 92. UAE cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 93. Kuwait cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 94. Kuwait cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 95. Kuwait cell viability assay market, end-user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cell viability assay, market segmentation
  • Fig. 8 Market snapshot, 2021
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Market challenge relevance analysis (current & future impact)
  • Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Market penetration vs growth prospect mapping, 2021
  • Fig. 16 Global cell viability assay market: product movement analysis
  • Fig. 17 Global cell viability assay market, for consumables, 2018 - 2030 (USD Million)
  • Fig. 18 Global cell viability assay market, for reagents and assay kits, by type, 2018 - 2030 (USD Million)
  • Fig. 19 Global cell viability assay market, for dye exclusion assays, 2018 - 2030 (USD Million)
  • Fig. 20 Global cell viability assay market, for colorimetric assays, 2018 - 2030 (USD Million)
  • Fig. 21 Global cell viability assay market, for fluorometric assays, 2018 - 2030 (USD Million)
  • Fig. 22 Global cell viability assay market, for luminometric assays, 2018 - 2030 (USD Million)
  • Fig. 23 Global cell viability assay market, for microplates, 2018 - 2030 (USD Million)
  • Fig. 24 Global cell viability assay market, for insturments, 2018 - 2030 (USD Million)
  • Fig. 25 Global cell viability assay market, for spectrophotometer, 2018 - 2030 (USD Million)
  • Fig. 26 Global cell viability assay market, for microscopy, 2018 - 2030 (USD Million)
  • Fig. 27 Global cell viability assay market, for cell imaging and analysis system, 2018 - 2030 (USD Million)
  • Fig. 28 Global cell viability assay market, for others, 2018 - 2030 (USD Million)
  • Fig. 29 Global cell viability assay market, for microplates, 2018 - 2030 (USD Million)
  • Fig. 30 Global cell viability assay market: application movement analysis
  • Fig. 31 Global cell viability assay market, for drug discovery and development, 2018 - 2030 (USD Million)
  • Fig. 32 Global cell viability assay market, for stem cell research, 2018 - 2030 (USD Million)
  • Fig. 33 Global cell viability assay market, for stem cell research, 2018 - 2030 (USD Million)
  • Fig. 34 Global cell viability assay market: end-user movement analysis
  • Fig. 35 Global cell viability assay market, for biopharmaceutical & pharmaceutical companies, 2018 - 2030 (USD Million)
  • Fig. 36 Global cell viability assay market, for CROSs & CMOs, 2018 - 2030 (USD Million)
  • Fig. 37 Global cell viability assay market, for academic & research institutes, 2018 - 2030 (USD Million)
  • Fig. 38 Global cell viability assay market, for diagnostic labs, 2018 - 2030 (USD Million)
  • Fig. 39 Regional marketplace: key takeaways
  • Fig. 40 Regional outlook, 2021 & 2030
  • Fig. 41 Global flow cytometry market: regional movement analysis
  • Fig. 42 North America cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 44 Canada cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 46 U.K. cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 47 Germany cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 48 France cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia pacific cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 55 China cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 56 India cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 57 Japan cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 63 Mexico cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 65 Middle East and Africa cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 67 Saudi Arabia cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 68 UAE cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 69 Kuwait cell viability assay market, 2018 - 2030 (USD Million)